Bulls vs Bears updated 6/18/15
Bullish
- FDA Imetelstat hold removed on 11/3/14
- Janssen to initiate a Phase 2 study in patients with myelofibrosis in mid-2015,
- Followed by a Phase 2 study in patients with myelodysplastic syndromes at the end of 2015
- Good support at $1.75 due insider buy on 5/9/2014
Bearish
- Single candidate, Imetelstat has blemished history, clinical trial put on hold 3/12/14
- Imetelstat, toxicity issues
- Mgmt sued for SEC misconduct
- Large insider sale on 3/2015 70K@$4.10
No comments:
Post a Comment